Drug intelligence / Profile preview

MY012

Development stage: Preclinical
Lead developer: Mabylon
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

MY012 is a monoclonal antibody developed by Mabylon AG that targets the Apoptosis-associated speck-like protein containing a CARD (ASC), a central component of the inflammasome. During chronic inflammation, ASC forms large extracellular complexes known as 'ASC specks' that are released from cells and serve to propagate and amplify inflammatory signaling. MY012 is designed to neutralize these extracellular ASC specks, thereby halting the cycle of inflammation. The program is currently in preclinical development for the treatment of inflammatory bowel disease (IBD) and neuroinflammatory disorders.

Other names: anti-ASC antibody

Targets

PYCARD (Apoptosis-associated speck-like protein containing a CARD)

Beyond the preview

Go deeper on MY012.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MY012.

Explore the full profile